Precision Cancer Medicines for Patients With Genetically Defined Cancers
Expanding the Reach of Precision Medicine Through the Development of Novel MasterKey Therapies
Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond’s proprietary approach is based upon a deep understanding of cancer genetics, onco-protein function, and drug discovery.
The Company’s proprietary MAP discovery engine is designed to allow Black Diamond to analyze population-level genetic sequencing data and real world evidence (RWE) to identify oncogenic mutations that promote cancer, de-orphan them, and develop MasterKey therapies that selectively target families of oncogenic mutations.
The cornerstone of our approach derives from evolving practices in the management of patients with cancer in targeted oncology therapies. Genetic sequencing of cancers has become increasingly widespread, leading to the discovery of many genetic alterations which were previously unaddressed, unsuccessfully targeted or overlooked. Today, new families of undrugged oncogenic targets have been identified, revealing a significant unmet medical need and emerging opportunity to deliver for novel targeted therapies that can extend precision medicines to patients with cancer.
Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. Together with Versant Ventures in 2017, Black Diamond began building its MAP discovery engine. Versant’s Ridgeline team of scientists, along with Black Diamond scientist Matthew O’Connor, were instrumental in helping define drug discovery strategies, identify initial core programs and validate the MAP discovery engine.